Clinical significance of repeat sextant biopsies in prostate cancer patients.

[1]  C. Begg,et al.  Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study. , 1997, British journal of urology.

[2]  D. Bostwick,et al.  Prediction of capsular perforation and seminal vesicle invasion in prostate cancer. , 1996, The Journal of urology.

[3]  C. Roehrborn,et al.  Diagnostic yield of repeated transrectal ultrasound-guided biopsies stratified by specific histopathologic diagnoses and prostate specific antigen levels. , 1996, Urology.

[4]  D. Wood,et al.  Randomized Prospective Study Comparing Radical Prostatectomy Alone Versus Radical Prostatectomy Preceded by Androgen Blockage in Clinical Stage B2 (T2bNxM0) Prostate Cancer , 1995 .

[5]  L. Baert,et al.  Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. The Belgian Uro-Oncological Study Group. , 1995, The Journal of urology.

[6]  W. Ellis,et al.  Repeat prostate needle biopsy: who needs it? , 1995, The Journal of urology.

[7]  G. D. Taylor,et al.  Computer simulation of the probability of detecting low volume carcinoma of the prostate with six random systematic core biopsies. , 1995, Urology.

[8]  R. Badalament,et al.  Sextant prostate biopsies. A histopathologic correlation with radical prostatectomy specimens , 1995, Cancer.

[9]  T. Stamey,et al.  Making the most out of six systematic sextant biopsies. , 1995, Urology.

[10]  C. Busch,et al.  Standardized in vitro mapping with multiple core biopsies of total prostatectomy specimens: localization and prediction of tumour volume and grade. , 1994, British journal of urology.

[11]  M. Toublanc,et al.  Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy. , 1994, Urology.

[12]  W. Catalona,et al.  Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. , 1994, The Journal of urology.

[13]  P. Walsh,et al.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.

[14]  H. Huland,et al.  Systematic sextant biopsies in 651 patients referred for prostate evaluation. , 1994, The Journal of urology.

[15]  V. Reuter,et al.  Use of neoadjuvant androgen deprivation therapy in clinically localized prostate cancer. , 1993, Clinical and investigative medicine. Medecine clinique et experimentale.

[16]  B. Têtu,et al.  Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. , 1993, Clinical and investigative medicine. Medecine clinique et experimentale.

[17]  N. Olson,et al.  Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. , 1993, The Journal of urology.

[18]  M. Terris,et al.  Detection of clinically significant prostate cancer by transrectal ultrasound-guided systematic biopsies. , 1992, The Journal of urology.

[19]  D. Prapotnich,et al.  Systematic prostatic biopsies in 100 men with no suspicion of cancer on digital rectal examination. , 1991, The Journal of urology.

[20]  M. Rifkin,et al.  Palpable masses in the prostate: superior accuracy of US-guided biopsy compared with accuracy of digitally guided biopsy. , 1991, Radiology.

[21]  M. Terris,et al.  Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. , 1989, The Journal of urology.